These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The hypotensive efficacy of dorzolamide HCL-timolol maleate 0.50% vs concomitant use of the two drugs. Durante A; Aurilia P; Guarnaccia G; Boles Carenini B Acta Ophthalmol Scand Suppl; 2000; (232):46. PubMed ID: 11235533 [No Abstract] [Full Text] [Related]
6. Comparison of the efficacy on intraocular pressure and retinal blood flow of a beta-blocker (timolol maleate) against the fixed association of a topical carbonic anhydrase (dorzolamide) and a beta-blocker (timolol maleate). Brogliatti B; Rolle T; Vizzeri GM; Cipullo D Acta Ophthalmol Scand Suppl; 2000; (232):47-9. PubMed ID: 11235534 [No Abstract] [Full Text] [Related]
7. Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Michaud JE; Friren B; Am J Ophthalmol; 2001 Aug; 132(2):235-43. PubMed ID: 11476685 [TBL] [Abstract][Full Text] [Related]
9. Clinical use of a topical carbonic anhydrase inhibitor in patients affected by chronic simple glaucoma. D'Andrea A; D'Andrea D; Ferreri G Acta Ophthalmol Scand Suppl; 1998; (227):36-8. PubMed ID: 9972339 [TBL] [Abstract][Full Text] [Related]
10. Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor. Lippa EA; Carlson LE; Ehinger B; Eriksson LO; Finnström K; Holmin C; Nilsson SE; Nyman K; Raitta C; Ringvold A Arch Ophthalmol; 1992 Apr; 110(4):495-9. PubMed ID: 1562255 [TBL] [Abstract][Full Text] [Related]
11. Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor. Wilkerson M; Cyrlin M; Lippa EA; Esposito D; Deasy D; Panebianco D; Fazio R; Yablonski M; Shields MB Arch Ophthalmol; 1993 Oct; 111(10):1343-50. PubMed ID: 8216014 [TBL] [Abstract][Full Text] [Related]
12. A single dose of the topical carbonic anhydrase inhibitor MK-927 decreases IOP in patients. Pfeiffer N; Hennekes R; Lippa EA; Grehn F; Garus H; Brunner-Ferber FL Br J Ophthalmol; 1990 Jul; 74(7):405-8. PubMed ID: 2198931 [TBL] [Abstract][Full Text] [Related]
13. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group. Strahlman E; Tipping R; Vogel R Arch Ophthalmol; 1995 Aug; 113(8):1009-16. PubMed ID: 7639651 [TBL] [Abstract][Full Text] [Related]
14. The long-term safety and efficacy of brinzolamide 1.0% (azopt) in patients with primary open-angle glaucoma or ocular hypertension. The Brinzolamide Long-Term Therapy Study Group. March WF; Ochsner KI Am J Ophthalmol; 2000 Feb; 129(2):136-43. PubMed ID: 10682964 [TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of dorzolamide vs. pilocarpine for primary open-angle glaucoma. Rocchi A; Tingey D Can J Ophthalmol; 1997 Oct; 32(6):414-8. PubMed ID: 9363347 [No Abstract] [Full Text] [Related]
17. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension. Stewart WC; Sharpe ED; Day DG; Kolker AE; Konstas AG; Lee WH; Rieser JC; Chopra H; Holmes KT J Ocul Pharmacol Ther; 2000 Jun; 16(3):251-9. PubMed ID: 10872922 [TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group. Silver LH Am J Ophthalmol; 1998 Sep; 126(3):400-8. PubMed ID: 9744373 [TBL] [Abstract][Full Text] [Related]
19. Hypotensive effects of dorzolamide eyewash in maximal therapy glaucoma patients: a comparative study with oral acetazolamide. Manni GL; Centofanti M; Napoli D; Parisi V; Bucci MG Acta Ophthalmol Scand Suppl; 1997; (224):22-3. PubMed ID: 9589714 [No Abstract] [Full Text] [Related]
20. [Impact of prostaglandin-F(2alpha)-analogues and carbonic anhydrase inhibitors on central corneal thickness -- a cross-sectional study on 403 eyes]. Viestenz A; Martus P; Schlötzer-Schrehardt U; Langenbucher A; Mardin CY Klin Monbl Augenheilkd; 2004 Sep; 221(9):753-6. PubMed ID: 15459842 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]